What are the 2025 guidelines for the management of adult systemic lupus erythematosus?

2025 SLE Management Guidelines

The 2025 American College of Rheumatology (ACR) guideline for systemic lupus erythematosus emphasizes universal hydroxychloroquine treatment, aggressive glucocorticoid minimization, and early introduction of conventional and/or biologic immunosuppressive therapies to achieve remission or low disease activity while reducing SLE-related mortality and treatment toxicity 1, 2.

Core Treatment Principles

Hydroxychloroquine as Foundation Therapy

• All patients with SLE should receive hydroxychloroquine unless contraindicated 1, 2
• This represents the backbone of SLE treatment across all guidelines 3
• Benefits include prevention of infections, thrombosis, and improved survival 3
• Monitor for retinal toxicity, which correlates with longer duration and higher cumulative dose 3

Glucocorticoid Minimization Strategy

Limit glucocorticoid duration and maintain doses ≤5 mg/day prednisone equivalent 3, 1, 2. The evidence is clear:

• Chronic glucocorticoid use correlates with infections, osteonecrosis, and irreversible organ damage 3
• The maximum maintenance dose was lowered from 7.5 mg/day to 5 mg/day based on observational studies showing increased adverse events above this threshold 3
• Use steroid-sparing agents to facilitate rapid glucocorticoid taper 4

Early Immunosuppressive Therapy

Introduce conventional and/or biologic immunosuppressive therapies early to achieve disease control 1, 2. The treatment goal is:

• Remission or low disease activity (treat-to-target approach) 1, 2, 5
• Minimize medication-related toxicities while preventing organ damage 1, 2

Biologic Therapies

The approved biologics with high-quality randomized controlled trial evidence include:

• Anifrolumab: Proven efficacy with organ-specific endpoints including CLASI for skin and joint counts 3
• Belimumab: Demonstrated efficacy using SLEDAI and BILAG domains 3

These biologics should be considered as steroid-sparing agents and for achieving treatment targets 3, 1, 2.

Non-Pharmacological Management

The 2024 EULAR recommendations for non-pharmacological management provide complementary guidance 6:

• Photoprotection is essential for all SLE patients 6
• Smoking cessation should be actively promoted 6
• Regular physical exercise should be encouraged 6
• Psychosocial interventions are important given the chronic disease burden 6
• Patient education and self-management support are fundamental 6

Vaccination Recommendations

Based on the systematic literature review informing EULAR guidelines 3:

COVID-19 Vaccination

• Seropositivity rate of 81.1% following vaccination (higher with mRNA vaccines) 3
• Flare rate of 5.5%, with moderate/severe flares in only 0-2% of patients 3
• Vaccinate all SLE patients with available COVID-19 vaccines

Herpes Zoster Vaccination

• Use recombinant zoster vaccine (not live attenuated) 3
• No statistically significant increase in flares following recombinant vaccine in >4500 SLE patients 3
• The live attenuated vaccine showed only mild/moderate flares in 2/90 patients but is not preferred 3

Monitoring and Disease Assessment

Distinguish between disease activity and cumulative damage 5:

• Disease activity represents current inflammation requiring immunosuppression
• Damage represents irreversible organ injury from disease or treatment
• Regular monitoring should assess both parameters to guide therapy adjustments

Pregnancy Management

Preconception planning is critical 4:

• Assess disease activity, major organ involvement, and hypercoagulability status before conception 4
• For patients with antiphospholipid antibodies, prescribe low-dose aspirin prophylaxis 4
• Multidisciplinary care with close monitoring optimizes maternal and fetal outcomes 4
• Long-term anticoagulation is essential for secondary antiphospholipid syndrome prevention 4

Organ-Specific Considerations

Lupus Nephritis

A separate 2025 ACR guideline addresses lupus nephritis specifically 1, 2. The 2025 EULAR guideline also provides updated recommendations 7. Key themes include:

• Early combination regimens targeting complementary immune pathways 7
• Rapid glucocorticoid minimization strategies 7
• Incorporation of renoprotective therapy as central to chronic kidney disease management 7
• Emerging targeted therapies: belimumab, voclosporin, and obinutuzumab 7

Cardiopulmonary Manifestations

For serious inflammatory cardiopulmonary involvement 8:

• Glucocorticoids remain first-line for pericarditis, myocarditis, pleuritis, acute lupus pneumonitis, and diffuse alveolar hemorrhage 8
• Glucocorticoid pulse therapy for life-threatening manifestations (pericardial tamponade, lupus myocarditis, diffuse alveolar hemorrhage) 8
• Cyclophosphamide is the most evidence-based immunosuppressant for severe cardiopulmonary disease 8
• Rituximab as second-line therapy for lupus myocarditis, diffuse alveolar hemorrhage, and shrinking lung syndrome 8
• Plasma exchange commonly used in diffuse alveolar hemorrhage 8

Critical caveat: Despite aggressive immunosuppression, lupus myocarditis, acute lupus pneumonitis, and diffuse alveolar hemorrhage carry 40-60% short-term mortality 8.

Pulmonary Arterial Hypertension

• PAH-targeted therapies have high-quality RCT evidence 8
• Initial combination PAH-targeted therapy superior to monotherapy 8
• Immunosuppressive therapy may benefit SLE-PAH patients, especially those with early, mild disease 8

Implementation Across Healthcare Systems

The 2026 British Society for Rheumatology guideline emphasizes 9:

• Structured collaboration between rheumatology and non-rheumatology clinicians
• Equitable access to care to address disparities
• Life-course approach applicable to children, young people, and adults

Common Pitfalls to Avoid

1. Delaying rheumatology referral: Timely specialist access is critical for accurate diagnosis and prompt treatment 4
2. Prolonged high-dose glucocorticoids: Increases irreversible damage without improving long-term outcomes 3
3. Inadequate hydroxychloroquine adherence monitoring: Regular assessment is essential 4
4. Underestimating cardiovascular risk: Aggressive prevention of cardiovascular disease and osteoporosis is mandatory 5
5. Insufficient retinal toxicity screening: Monitor cumulative hydroxychloroquine dose and duration 3

Research Gaps

Current evidence limitations include 8:

• Minimal data on belimumab and anifrolumab for cardiopulmonary manifestations
• No evidence supporting anti-fibrotic therapy (nintedanib, pirfenidone) for SLE-interstitial lung disease
• Urgent need for RCTs in life-threatening cardiopulmonary disease given persistent high mortality